Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease

Abhijit A. Date, Rana Rais, Taarika Babu, Jairo Ortiz, Pranjali Kanvinde, Ajit G. Thomas, Sarah C. Zimmermann, Alexandra J. Gadiano, Gilad Halpert, Barbara S. Slusher, Laura M. Ensign

Research output: Contribution to journalArticle

Abstract

Here we evaluate the potential for local administration of a small molecule FOLH1/GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) as a novel treatment for inflammatory bowel disease (IBD). We found that FOLH1/GCPII enzyme activity was increased in the colorectal tissues of mice with TNBS-induced colitis, and confirmed that 2-PMPA inhibited FOLH1/GCPII enzyme activity ex vivo. In order to maximize local enema delivery of 2-PMPA, we studied the effect of vehicle tonicity on the absorption of 2-PMPA in the colon. Local administration of 2-PMPA in a hypotonic enema vehicle resulted in increased colorectal tissue absorption at 30 min compared to 2-PMPA administered in an isotonic enema vehicle. Furthermore, local delivery of 2-PMPA in hypotonic enema vehicle resulted in prolonged drug concentrations for at least 24 h with minimal systemic exposure. Finally, daily treatment with the hypotonic 2-PMPA enema ameliorated macroscopic and microscopic symptoms of IBD in the TNBS-induced colitis mouse model, indicating the potential of FOLH1/GCPII inhibitors for the local treatment of IBD.

Original languageEnglish (US)
Pages (from-to)132-138
Number of pages7
JournalJournal of Controlled Release
Volume263
DOIs
StatePublished - Oct 10 2017

Keywords

  • 2-PMPA
  • Colitis
  • Folate polyglutamate
  • Hypotonic
  • N-acetyl-aspartyl glutamate
  • TNBS

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this